A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

~41 mi. (Córdoba, Spain, +89 more cities)

Hospital Universitario Reina Sofia; Servicio de Farmacia

ER Positive, +1 more biomarker

Breast Carcinoma

giredestrant, +1 more drug

hormone therapy

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

~41 mi. (Córdoba, Spain, +120 more cities)

Hospital Universitario Reina Sofia; Servicio de Oncologia

PD-L1 Expression (CPS >= 1), +5 more biomarkers

Infiltrating Bladder Urothelial Carcinoma

atezolizumab

immunotherapy

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

~41 mi. (Córdoba, Spain, +69 more cities)

Hospital Universitario Reina Sofia

Cervical Adenocarcinoma, +2 more conditions

tisotumab vedotin

chemotherapy, +1 more type

Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

~41 mi. (Córdoba, Spain, +120 more cities)

Hospital Universitario Reina Sofía

FGFR3 A391E, +9 more biomarkers

Urothelial Carcinoma

infigratinib

targeted therapy

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

~41 mi. (Córdoba, Spain, +39 more cities)

Novartis Investigative Site

Fallopian Tube Carcinoma, +3 more conditions

alpelisib, +1 more drug

targeted therapy

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

~41 mi. (Córdoba, Spain, +29 more cities)

Hospital Universitario 12 de Octubre

MAGEA4 Expression

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells

cellular therapy, +1 more type

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

~41 mi. (Córdoba, Spain, +10 more cities)

Hospital Universitario Reina Sofia

ER Positive, +2 more biomarkers

Breast Carcinoma

abemaciclib, +2 more drugs

hormone therapy, +1 more type

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

~80 mi. (Jaén, Spain, +160 more cities)

H. U. de Jaén

FOLR1 Expression

Fallopian Tube Carcinoma, +2 more conditions

mirvetuximab soravtansine

chemotherapy, +1 more type

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~80 mi. (Jaén, Spain, +184 more cities)

Complejo Hospitalario de Jaén

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

~80 mi. (Jaén, Spain, +37 more cities)

Complejo Hospitalario de Jaen

ER Negative, +2 more biomarkers

Breast Carcinoma

ladiratuzumab vedotin, +1 more drug

chemotherapy, +2 more types